Researchers at the 2022 ASCO Annual Meeting examined the prevalence of prior authorization for PARP inhibitors among patients with ovarian cancer overall, by frontline or recurrent maintenance, and by genetic status.
Researchers at the 2022 ASCO Annual Meeting examined the prevalence of prior authorization for PARP inhibitors among patients with ovarian cancer overall, by frontline or recurrent maintenance, and by genetic status.
Researchers at the 2022 ASCO...